Skip to main content

Table 2 The pooled ORs and 95%CIs for the association between TNF polymorphisms and prostate cancer susceptibility in total and stratified analysis

From: No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-α gene and susceptibility to prostate cancer: a comprehensive meta-analysis

Variables

N

Case/Control

M-allele vs. W-allele

OR(95%CI) PhP

MW vs. WW

OR(95%CI) PhP

MM + MW vs. WW

OR(95%CI) PhP

rs1800629

 Total

22

6936/7619

1.03 (0.92–1.16)0.001 0.580

1.04 (0.93–1.17)0.040 0.486

1.06 (0.94–1.18)0.013 0.353

 HWE

18

7485/6792

1.03 (0,92–1.16)0.006 0.584

1.04 (0,93–1.16)0.091 0.509

1.05 (0,94–1.17)0.051 0.429

Ethnicity

 Asian

8

964/1137

1.03 (0.68–1.56)0.000 0.881

1.04 (0.70–1.56)0.038 0.845

1.09 (0.70–1.71)0.006 0.698

 Caucasian

12

5626/5817

1.01 (0.94–1.08)0.223 0.838

1.02 (0.94–1.11)0.525 0.672

1.02 (0.94–1.11)0.433 0.625

 African-American

2

346/665

0.93 (0.47–1.86)0.049 0.843

0.87 (0.28–2.67)0.009 0.804

0.90 (0.34–2.37)0.016 0.829

SOC

 HB

14

2579/2973

1.02 (0.86–1.22)0.012 0.787

1.00 (0.81–1.22)0.023 0.972

1.01 (0.82–1.24)0.012 0.787

 PB

8

4357/4646

1.04 (0.89–1.22)0.009 0.600

1.04 (0.94–1.14)0.298 0.483

1.04 (0.95–1.14)0.199 0.425

Genotyping

 Others

5

977/1309

1.07 (0.91–1.26)0.420 0.420

0.97 (0.62–1.53)0.021 0.900

1.07 (0.79–1.45)0.079 0.668

 Sequencing

2

546/530

0.94 (0.75–1.19)0.166 0.608

0.76 (0.34–1.70)0.055 0.505

0.80 (0.41–1.55)0.086 0.506

 TaqMan

7

4456/4733

1.04 (0.92–1.17)0.081 0.520

1.02 (0.93–1.12)0.278 0.638

1.02 (0.93–1.12)0.152 0.672

 PCR-RFLP

5

463/562

0.74 (0.43–1.28)0.030 0.280

0.90 (0.63–1.29)0.263 0.565

0.89 (0.63–1.26)0.186 0.520

 ARMS-PCR

3

494/485

1.56 (0.74–3.29)0.001 0.239

1.28 (0.93–1.78)0.163 0.135

1.54 (0.80–2.97)0.024 0.192

rs361525

 Total

8

2212/2222

0.93 (0.66–1.32)0.007 0.684

0.86 (0.52–1.41)0.000 0.542

0.85 (0.52–1.39)0.000 0.525

 HWE

6

2043/1979

1.11 (0,91–1.35)0.111 0.321

1.02 (0,69–1.52)0.055 0.905

1.05 (0,73–1.52)0.803 0.794

Ethnicity

 Asian

3

450/470

0.72 (0.34–1.50)0.039 0.380

0.55 (0.15–1.99)0.002 0.360

0.54 (0.15–2.00)0.001 0.357

 Caucasian

4

1698/1624

1.16 (0.94–1.44)0.673 0.164

1.16 (0.94–1.44)0.673 0.164

1.16 (0.94–1.44)0.673 0.164

 African-American

1

64/126

Genotyping

 Others

2

178/188

0.65 (0.47–0.89)0.111 0.008

0.44 (0.09–2.25)0.002 0.326

0.44 (0.08–2.28)0.002 0.325

 Sequencing

2

535/511

1.07 (0.72–1.57)0.595 0.746

0.90 (0.59–1.38)0.590 0.633

0.98 (0.65–1.48)0.999 0.936

 PCR-RFLP

2

140/150

2.59 (0.98–6.85)0.628 0.055

2.68 (1.00–7.20)0.626 0.050

2.68 (1.00–7.20)0.626 0.050

 TaqMan

2

1359/1371

0.77 (0.30–2.01)0.017 0.599

0.78 (0.28–2.20)0.011 0.640

0.77 (0.28–2.13)0.013 0.620

rs1799724

 Total

5

2914/3121

0.95 (0.84–1.07)0.169 0.381

1.01 (0.80–1.27)0.054 0.951

0.95 (0.83–1.07)0.120 0.390

 HWE

3

2444/2735

0.99 (0,78–1.26)0.042 0.930

0.98 (0,74–1.30)0.037 0.896

0.99 (0,75–1.30)0.032 0.931

 Caucasian

3

2253/2493

0.90 (0.79–1.03)0.403 0.115

0.88 (0.76–1.02)0.196 0.082

0.88 (0.76–1.02)0.400 0.089

  1. Ph: value of Q-test for heterogeneity test; P: Z-test for the statistical significance of the OR; HB hospital-based, PB population-based, SOC source of control, PCR-FLIP polymerase chain reaction and restrictive fragment length polymorphism, ARMS amplification refractory mutation system HWE, Hardy–Weinberg equilibrium of control group, W wild type-allele, M mutant-allele